WALTHAM, Mass. — Revvity, Inc. (NYSE: RVTY) has introduced pHSense™, a new plate-based internalization reagent technology aimed at speeding the development of next-generation targeted therapeutics, particularly in G protein-coupled receptor (GPCR) and antibody-drug conjugate (ADC) research.
Designed for high-throughput workflows, pHSense combines a pH-sensitive dye with time-resolved fluorescence (TRF) readouts, enabling researchers to monitor antibody, ADC, or receptor internalization with high accuracy and strong signal-to-background ratios—even at low endogenous receptor expression levels. The reagents are compatible with standard plate readers and Revvity’s multimode detection platforms, allowing seamless integration into existing drug discovery processes.
By delivering robust internalization kinetics and improving detection capabilities, pHSense aims to help researchers streamline preclinical development, lower costs, and accelerate the path toward clinical evaluation.
“pHSense reagents fill a critical gap in internalization assay technologies, enabling researchers to gain faster, more reliable insights under physiologically relevant conditions,” said Craig Monell, senior vice president of reagents at Revvity. “This launch reinforces our commitment to advancing drug discovery with innovative tools that improve data quality, throughput, and reproducibility.”
The technology is expected to address growing needs in oncology and precision medicine, where receptor trafficking plays a key role. Revvity said pHSense overcomes limitations of current tools, such as low throughput and poor signal-to-noise ratios, supporting more efficient screening and characterization of therapeutic candidates.
